Hepatitis C virus infection elimination — the WHO target of eighty percent reduction in incidence and sixty-five percent reduction in mortality by 2030 — depends on direct-acting antiviral therapy's remarkable cure rates and expanding treatment access, with the Gastrointestinal Therapeutics Market reflecting both the therapeutic success of pangenotypic DAA regimens and the...